NCT03404960 - Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy | Biotech Hunter

Enrollment

104

Participants

Timeline

Start Date

January 31, 2018

Primary Completion Date

April 5, 2022

Study Completion Date

October 9, 2024

Conditions

Pancreatic Adenocarcinoma

Interventions

DRUG

Niraparib + Nivolumab

Niraparib 200mg PO daily on days 1-28 of each 28-day cycle. Nivolumab 480mg IV day 1 of each cycle.

DRUG

Niraparib + Ipilimumab

Niraparib 200mg PO daily on days 1-21 of each 21-day cycle. Ipilimumab 3mg/kg IV day 1 of each cycle, for the first 4 cycles only.

Trial Locations (1)

University of Pennsylvania, Abramson Cancer Center, Philadelphia